US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

140.48

+7.875.93%

Volume:438.87K

Turnover:61.17M

Market Cap:6.27B

PE:-14.41

High:142.49

Open:133.35

Low:133.31

Close:132.61

52wk High:166.48

52wk Low:41.50

Shares:44.67M

Float Shares:40.73M

Volume Ratio:0.61

T/O Rate:1.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.7487

EPS(LYR):-11.1105

ROE:-16.12%

ROA:-12.03%

PB:2.47

PE(LYR):-12.64

Loading ...

Overview Company News Filings

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Movement Alert｜GRAIL, Inc. Rises 5.97% in Regular Trading, FDA Advisory Committee Votes in Favor of Galleri Cancer Detection Test Approval

TD ups Grail approval probability to 95% after panel vote

PRESS Digest -Wall Street Journal - September 24

Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)

RBC Capital Sticks to Their Hold Rating for GRAIL Inc (GRAL)

Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval

FDA panel votes in favor of Grail’s Galleri benefits outweighing risks

US FDA Advisers Back Safety of Grail's Galleri Multi-Cancer Screening Test

THOMSON REUTERS

FDA panel says Grail’s cancer detection blood test is safe, Bloomberg says

Grail CEO Joshua J. Ofman Disposes of Common Shares Worth $5.54 Million

FDA Advisers are Reviewing a Multicancer-Detection Test. Medicare Coverage Could Follow.

Grail Trading Halted Ahead of FDA AdCom Meeting on Galleri Blood Test

NASDAQ Trade Halt Halt News Pending at 06:55 Am

With Approval Looking Likely, How Fast Will Sales of Cancer-Screening Blood Tests Rise?

Grail Gains From More Focused FDA Review Before Galleri Advisory Panel, UBS Says

MT Newswires Live

Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)

Under the Radar: Grail Shares Surge on FDA Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/GRAL/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRAL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":140.48,"timestamp":1791565046726,"preClose":132.61,"halted":0,"volume":438869,"delay":0,"changeRate":0.05934695724304333,"floatShares":40727891,"shares":44666200,"eps":-9.748709,"marketStatus":"Trading","change":7.87,"latestTime":"10-09 12:57:46 EDT","open":133.35,"high":142.49,"low":133.31,"amount":61173493.48624,"amplitude":0.069226,"askPrice":140.9,"askSize":47,"bidPrice":140.45,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-9.748709,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":132.61,"preHourTrading":{"tag":"盘前","latestPrice":133.41,"preClose":132.61,"latestTime":"09:29 EDT","volume":3413,"amount":458549.89483000006,"timestamp":1791552599999,"change":0.8,"changeRate":0.006033,"amplitude":0.041098},"postHourTrading":{"tag":"盘后","latestPrice":133.5,"preClose":132.61,"latestTime":"19:56 EDT","volume":10006,"amount":1328773.6661,"timestamp":1791503795888,"change":0.89,"changeRate":0.006711,"amplitude":0.014189},"volumeRatio":0.614316,"impliedVol":1.0116,"impliedVolPercentile":0.7331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","floatShares":40727891,"roa":"-12.03%","roe":"-16.12%","lyrEps":-11.110457,"volumeRatio":0.614316,"shares":44666200,"dividePrice":0,"high":142.49,"amplitude":0.069226,"preClose":132.61,"low":133.31,"week52Low":41.5,"pbRate":"2.47","psRate":"37.97","week52High":166.475,"institutionHeld":0,"latestPrice":140.48,"committee":-0.807692,"eps":-9.748709,"divideRate":0,"volume":438869,"delay":0,"ttmEps":-9.748709,"open":133.35,"prevYearClose":85.59,"prevWeekClose":143.26,"prevMonthClose":140.12,"prevQuarterClose":140.12,"fiveDayClose":143.26,"twentyDayClose":76.23,"sixtyDayClose":71.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRAL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"GRAL","fiscalQuarterEnding":"2026/06","expectedEps":-2.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":-2.56},{"market":"US","date":"2026-05-05","symbol":"GRAL","fiscalQuarterEnding":"2026/03","expectedEps":3,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"post","actualEps":-2.29},{"market":"US","date":"2026-02-19","symbol":"GRAL","fiscalQuarterEnding":"2025/12","expectedEps":-3.33,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":-1.86},{"market":"US","date":"2025-11-12","symbol":"GRAL","fiscalQuarterEnding":"2025/09","expectedEps":-3.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-2.46},{"market":"US","date":"2025-08-12","symbol":"GRAL","fiscalQuarterEnding":"2025/06","expectedEps":-3.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-3.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRAL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRAL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.25,"hold":0.5833,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":12,"updateTime":1791432000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRAL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRAL","date":"2026-10-08","current":-14.409087,"percent":0.008977,"low":-17.575081,"twenty":-7.844878,"median":-2.733989,"eighty":-0.305967,"high":-0.135365,"avg":-3.961994,"sd":3.909202,"marketCap":5936142498},"quantilePoints":[{"date":"2024-06-12","current":-0.243184,"twenty":-0.243184,"median":-0.243184,"eighty":-0.243184,"marketCap":362571424},{"date":"2024-06-28","current":-0.269888,"twenty":-0.264547,"median":-0.256536,"eighty":-0.248525,"marketCap":402385270},{"date":"2024-07-05","current":-0.275763,"twenty":-0.275763,"median":-0.271757,"eighty":-0.266328,"marketCap":411144316},{"date":"2024-07-12","current":-0.259385,"twenty":-0.273627,"median":-0.266328,"eighty":-0.249504,"marketCap":386725157},{"date":"2024-07-15","current":-0.263657,"twenty":-0.273022,"median":-0.264992,"eighty":-0.25148,"marketCap":393095372},{"date":"2024-08-02","current":-0.296236,"twenty":-0.274909,"median":-0.266328,"eighty":-0.253456,"marketCap":441668264},{"date":"2024-08-09","current":-0.310656,"twenty":-0.300615,"median":-0.272114,"eighty":-0.260667,"marketCap":463167741},{"date":"2024-08-16","current":-0.170902,"twenty":-0.29588,"median":-0.2706,"eighty":-0.248276,"marketCap":492749978},{"date":"2024-08-23","current":-0.178117,"twenty":-0.292284,"median":-0.264992,"eighty":-0.180551,"marketCap":513552907},{"date":"2024-08-30","current":-0.159595,"twenty":-0.28292,"median":-0.259385,"eighty":-0.170708,"marketCap":460148373},{"date":"2024-09-06","current":-0.145057,"twenty":-0.275763,"median":-0.247457,"eighty":-0.162201,"marketCap":418232023},{"date":"2024-09-13","current":-0.145918,"twenty":-0.275336,"median":-0.18151,"eighty":-0.152854,"marketCap":420715955},{"date":"2024-09-20","current":-0.149365,"twenty":-0.273627,"median":-0.178117,"eighty":-0.150075,"marketCap":430651682},{"date":"2024-09-27","current":-0.146457,"twenty":-0.273022,"median":-0.170741,"eighty":-0.146026,"marketCap":422268412},{"date":"2024-10-04","current":-0.135365,"twenty":-0.270458,"median":-0.165733,"eighty":-0.14454,"marketCap":390287790},{"date":"2024-10-11","current":-0.140319,"twenty":-0.269176,"median":-0.160133,"eighty":-0.142925,"marketCap":404570398},{"date":"2024-10-18","current":-0.152918,"twenty":-0.265794,"median":-0.156041,"eighty":-0.143463,"marketCap":440897901},{"date":"2024-10-25","current":-0.13978,"twenty":-0.263443,"median":-0.155556,"eighty":-0.143463,"marketCap":403017941},{"date":"2024-10-31","current":-0.146672,"twenty":-0.262589,"median":-0.153942,"eighty":-0.142688,"marketCap":422889395},{"date":"2024-11-08","current":-0.160456,"twenty":-0.259385,"median":-0.152918,"eighty":-0.142796,"marketCap":462632305},{"date":"2024-11-15","current":-0.250879,"twenty":-0.250879,"median":-0.154641,"eighty":-0.143442,"marketCap":531228205},{"date":"2024-11-22","current":-0.259924,"twenty":-0.250879,"median":-0.156041,"eighty":-0.143549,"marketCap":550380645},{"date":"2024-11-29","current":-0.277697,"twenty":-0.262044,"median":-0.156472,"eighty":-0.143635,"marketCap":588013510},{"date":"2024-12-06","current":-0.355611,"twenty":-0.27003,"median":-0.160025,"eighty":-0.14426,"marketCap":752993300},{"date":"2024-12-13","current":-0.329745,"twenty":-0.275763,"median":-0.161318,"eighty":-0.144928,"marketCap":698224042},{"date":"2024-12-20","current":-0.271984,"twenty":-0.27776,"median":-0.165841,"eighty":-0.145746,"marketCap":575917232},{"date":"2024-12-27","current":-0.308005,"twenty":-0.287312,"median":-0.170741,"eighty":-0.145918,"marketCap":652190984},{"date":"2025-01-03","current":-0.284362,"twenty":-0.289787,"median":-0.175532,"eighty":-0.146134,"marketCap":602125834},{"date":"2025-01-10","current":-0.280236,"twenty":-0.294514,"median":-0.180594,"eighty":-0.1465,"marketCap":593389633},{"date":"2025-01-17","current":-0.276189,"twenty":-0.293978,"median":-0.222157,"eighty":-0.146801,"marketCap":584821436},{"date":"2025-01-24","current":-0.412102,"twenty":-0.295346,"median":-0.234852,"eighty":-0.147318,"marketCap":872612048},{"date":"2025-01-31","current":-0.500013,"twenty":-0.298484,"median":-0.241319,"eighty":-0.14818,"marketCap":1058760325},{"date":"2025-02-07","current":-0.523498,"twenty":-0.307212,"median":-0.249504,"eighty":-0.148826,"marketCap":1108489468},{"date":"2025-02-14","current":-0.83436,"twenty":-0.31102,"median":-0.255132,"eighty":-0.149365,"marketCap":1766728591},{"date":"2025-02-21","current":-0.791697,"twenty":-0.321747,"median":-0.260916,"eighty":-0.149365,"marketCap":1604772870},{"date":"2025-02-28","current":-0.656882,"twenty":-0.34371,"median":-0.263657,"eighty":-0.149709,"marketCap":1331502572},{"date":"2025-03-07","current":-0.559345,"twenty":-0.359577,"median":-0.270244,"eighty":-0.149795,"marketCap":1133795978},{"date":"2025-03-14","current":-0.450152,"twenty":-0.414561,"median":-0.273627,"eighty":-0.15014,"marketCap":912460022},{"date":"2025-03-21","current":-0.465034,"twenty":-0.450921,"median":-0.275763,"eighty":-0.150484,"marketCap":942626791},{"date":"2025-03-28","current":-0.47791,"twenty":-0.468947,"median":-0.276427,"eighty":-0.150807,"marketCap":968726130},{"date":"2025-04-04","current":-0.416039,"twenty":-0.465703,"median":-0.277856,"eighty":-0.15113,"marketCap":843313720},{"date":"2025-04-11","current":-0.380338,"twenty":-0.459122,"median":-0.280236,"eighty":-0.151281,"marketCap":770947370},{"date":"2025-04-17","current":-0.443129,"twenty":-0.455455,"median":-0.281347,"eighty":-0.151562,"marketCap":898224019},{"date":"2025-04-25","current":-0.630246,"twenty":-0.466372,"median":-0.283965,"eighty":-0.151863,"marketCap":1277511821},{"date":"2025-05-02","current":-0.565758,"twenty":-0.478944,"median":-0.287218,"eighty":-0.15253,"marketCap":1146794916},{"date":"2025-05-09","current":-0.62862,"twenty":-0.498389,"median":-0.292296,"eighty":-0.15337,"marketCap":1274216573},{"date":"2025-05-16","current":-0.732698,"twenty":-0.51302,"median":-0.295346,"eighty":-0.153995,"marketCap":1402606531},{"date":"2025-05-23","current":-0.728564,"twenty":-0.527433,"median":-0.296725,"eighty":-0.154728,"marketCap":1394692362},{"date":"2025-05-30","current":-0.772349,"twenty":-0.542338,"median":-0.298484,"eighty":-0.155417,"marketCap":1478510603},{"date":"2025-06-06","current":-0.742094,"twenty":-0.562722,"median":-0.305137,"eighty":-0.155977,"marketCap":1420593278},{"date":"2025-06-13","current":-0.787758,"twenty":-0.602918,"median":-0.308322,"eighty":-0.156041,"marketCap":1508008868},{"date":"2025-06-20","current":-0.910282,"twenty":-0.617043,"median":-0.310838,"eighty":-0.156127,"marketCap":1742556049},{"date":"2025-06-27","current":-0.927946,"twenty":-0.628237,"median":-0.313683,"eighty":-0.156967,"marketCap":1776371133},{"date":"2025-07-03","current":-0.87796,"twenty":-0.640897,"median":-0.324667,"eighty":-0.158949,"marketCap":1680681639},{"date":"2025-07-11","current":-0.815382,"twenty":-0.656882,"median":-0.33641,"eighty":-0.159595,"marketCap":1560889904},{"date":"2025-07-18","current":-0.675007,"twenty":-0.694504,"median":-0.351643,"eighty":-0.160456,"marketCap":1292167904},{"date":"2025-07-25","current":-0.746416,"twenty":-0.703946,"median":-0.35847,"eighty":-0.160672,"marketCap":1428867181},{"date":"2025-08-01","current":-0.642872,"twenty":-0.704698,"median":-0.372061,"eighty":-0.161318,"marketCap":1230653229},{"date":"2025-08-08","current":-0.619382,"twenty":-0.703946,"median":-0.384644,"eighty":-0.164764,"marketCap":1185686362},{"date":"2025-08-15","current":-2.618835,"twenty":-0.718416,"median":-0.412102,"eighty":-0.165733,"marketCap":1160018171},{"date":"2025-08-22","current":-2.697774,"twenty":-0.721799,"median":-0.415789,"eighty":-0.165949,"marketCap":1194984536},{"date":"2025-08-29","current":-2.7759,"twenty":-0.732698,"median":-0.419718,"eighty":-0.170579,"marketCap":1229590423},{"date":"2025-09-05","current":-2.733582,"twenty":-0.742958,"median":-0.427076,"eighty":-0.170837,"marketCap":1210845568},{"date":"2025-09-12","current":-3.145369,"twenty":-0.751941,"median":-0.435395,"eighty":-0.172539,"marketCap":1393247431},{"date":"2025-09-19","current":-3.221867,"twenty":-0.757193,"median":-0.443129,"eighty":-0.177083,"marketCap":1427132362},{"date":"2025-09-26","current":-3.927439,"twenty":-0.772199,"median":-0.450236,"eighty":-0.179927,"marketCap":1739666779},{"date":"2025-10-03","current":-5.267781,"twenty":-0.790326,"median":-0.453995,"eighty":-0.180724,"marketCap":2333374029},{"date":"2025-10-10","current":-5.788618,"twenty":-0.792794,"median":-0.466707,"eighty":-0.18193,"marketCap":2564079942},{"date":"2025-10-17","current":-7.032117,"twenty":-0.810572,"median":-0.474733,"eighty":-0.214168,"marketCap":3114890311},{"date":"2025-10-24","current":-6.726125,"twenty":-0.834423,"median":-0.483801,"eighty":-0.232186,"marketCap":2979350587},{"date":"2025-10-31","current":-7.417862,"twenty":-0.86879,"median":-0.497307,"eighty":-0.23482,"marketCap":3285756878},{"date":"2025-11-07","current":-6.515349,"twenty":-0.90953,"median":-0.508594,"eighty":-0.23627,"marketCap":2885986787},{"date":"2025-11-14","current":-7.32206,"twenty":-1.284423,"median":-0.515869,"eighty":-0.238888,"marketCap":3243320953},{"date":"2025-11-21","current":-8.218834,"twenty":-2.622741,"median":-0.524768,"eighty":-0.242438,"marketCap":3338827399},{"date":"2025-11-28","current":-10.592844,"twenty":-2.668803,"median":-0.533066,"eighty":-0.245748,"marketCap":4303247596},{"date":"2025-12-05","current":-10.047321,"twenty":-2.733908,"median":-0.545714,"eighty":-0.248685,"marketCap":4081633659},{"date":"2025-12-12","current":-9.121802,"twenty":-2.773947,"median":-0.559678,"eighty":-0.249586,"marketCap":3705650118},{"date":"2025-12-19","current":-8.474563,"twenty":-3.023948,"median":-0.565758,"eighty":-0.250383,"marketCap":3442715024},{"date":"2025-12-26","current":-8.814736,"twenty":-3.115583,"median":-0.600672,"eighty":-0.254281,"marketCap":3580907004},{"date":"2026-01-02","current":-8.213077,"twenty":-3.191837,"median":-0.607471,"eighty":-0.259493,"marketCap":3336488466},{"date":"2026-01-09","current":-9.407758,"twenty":-3.756539,"median":-0.615248,"eighty":-0.260321,"marketCap":3821817142},{"date":"2026-01-16","current":-9.350183,"twenty":-4.63773,"median":-0.618067,"eighty":-0.262044,"marketCap":3798427809},{"date":"2026-01-23","current":-11.136928,"twenty":-5.050494,"median":-0.621638,"eighty":-0.262589,"marketCap":4524276801},{"date":"2026-01-30","current":-9.689876,"twenty":-5.381714,"median":-0.623725,"eighty":-0.263657,"marketCap":3936424878},{"date":"2026-02-06","current":-9.025844,"twenty":-5.92371,"median":-0.62862,"eighty":-0.266328,"marketCap":3666667895},{"date":"2026-02-13","current":-9.201448,"twenty":-6.490935,"median":-0.634416,"eighty":-0.269888,"marketCap":3738005363},{"date":"2026-02-20","current":-10.027753,"twenty":-6.738169,"median":-0.640672,"eighty":-0.270458,"marketCap":4094842980},{"date":"2026-02-27","current":-5.738328,"twenty":-6.59852,"median":-0.642551,"eighty":-0.271707,"marketCap":2343252016},{"date":"2026-03-06","current":-5.1161,"twenty":-6.525603,"median":-0.645131,"eighty":-0.273298,"marketCap":2089164448},{"date":"2026-03-13","current":-4.454105,"twenty":-6.495818,"median":-0.656882,"eighty":-0.273627,"marketCap":1818838106},{"date":"2026-03-20","current":-4.868977,"twenty":-6.467497,"median":-0.678025,"eighty":-0.275336,"marketCap":1988251759},{"date":"2026-03-27","current":-5.23965,"twenty":-6.370491,"median":-0.694504,"eighty":-0.275763,"marketCap":2139616500},{"date":"2026-04-02","current":-5.384303,"twenty":-6.22661,"median":-0.703946,"eighty":-0.276019,"marketCap":2198685668},{"date":"2026-04-10","current":-4.777565,"twenty":-6.012578,"median":-0.718792,"eighty":-0.276332,"marketCap":1950923327},{"date":"2026-04-17","current":-4.969431,"twenty":-5.842655,"median":-0.720859,"eighty":-0.277189,"marketCap":2029272014},{"date":"2026-04-24","current":-5.087966,"twenty":-5.758444,"median":-0.724241,"eighty":-0.277697,"marketCap":2077675915},{"date":"2026-05-01","current":-5.472702,"twenty":-5.73481,"median":-0.732698,"eighty":-0.277887,"marketCap":2234783492},{"date":"2026-05-08","current":-6.830613,"twenty":-5.758444,"median":-0.740497,"eighty":-0.278585,"marketCap":2700312031},{"date":"2026-05-15","current":-6.709025,"twenty":-6.393277,"median":-0.747877,"eighty":-0.279728,"marketCap":2652245447},{"date":"2026-05-22","current":-7.366901,"twenty":-6.535065,"median":-0.752054,"eighty":-0.280426,"marketCap":2912320000},{"date":"2026-05-29","current":-8.024776,"twenty":-6.608933,"median":-0.75506,"eighty":-0.280871,"marketCap":3172394554},{"date":"2026-06-05","current":-7.224687,"twenty":-6.675155,"median":-0.757458,"eighty":-0.282109,"marketCap":2856099264},{"date":"2026-06-12","current":-6.530986,"twenty":-6.667338,"median":-0.770188,"eighty":-0.283378,"marketCap":2581862234},{"date":"2026-06-18","current":-6.453909,"twenty":-6.64758,"median":-0.774322,"eighty":-0.283727,"marketCap":2551391453},{"date":"2026-06-26","current":-7.226858,"twenty":-6.705551,"median":-0.790201,"eighty":-0.284901,"marketCap":2856957596},{"date":"2026-07-02","current":-7.394041,"twenty":-6.741593,"median":-0.791697,"eighty":-0.287059,"marketCap":2923049149},{"date":"2026-07-10","current":-8.227784,"twenty":-6.830613,"median":-0.793866,"eighty":-0.287218,"marketCap":3252648583},{"date":"2026-07-17","current":-7.811998,"twenty":-6.920316,"median":-0.805047,"eighty":-0.287691,"marketCap":3088278032},{"date":"2026-07-24","current":-7.638301,"twenty":-7.010823,"median":-0.819893,"eighty":-0.291185,"marketCap":3019611483},{"date":"2026-07-31","current":-7.722978,"twenty":-7.028862,"median":-0.830133,"eighty":-0.292962,"marketCap":3053086426},{"date":"2026-08-07","current":-7.231699,"twenty":-7.225121,"median":-0.842819,"eighty":-0.294422,"marketCap":2831839235},{"date":"2026-08-14","current":-7.783772,"twenty":-7.278539,"median":-0.870399,"eighty":-0.295212,"marketCap":3048023808},{"date":"2026-08-21","current":-8.893621,"twenty":-7.372329,"median":-0.87796,"eighty":-0.295699,"marketCap":3482626264},{"date":"2026-08-28","current":-9.410334,"twenty":-7.428129,"median":-0.917705,"eighty":-0.296146,"marketCap":3684964305},{"date":"2026-09-04","current":-9.195892,"twenty":-7.480979,"median":-0.966282,"eighty":-0.297019,"marketCap":3600991785},{"date":"2026-09-11","current":-8.846854,"twenty":-7.492831,"median":-2.572448,"eighty":-0.297976,"marketCap":3464313109},{"date":"2026-09-18","current":-9.119469,"twenty":-7.639447,"median":-2.628601,"eighty":-0.298484,"marketCap":3571065408},{"date":"2026-09-25","current":-14.282035,"twenty":-7.746291,"median":-2.668477,"eighty":-0.301515,"marketCap":5592659159},{"date":"2026-10-02","current":-15.12041,"twenty":-7.801576,"median":-2.688619,"eighty":-0.304496,"marketCap":5920955979},{"date":"2026-10-08","current":-15.159192,"twenty":-7.844878,"median":-2.733989,"eighty":-0.305967,"marketCap":5936142498}],"updateTime":1791564502702},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRAL\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670412443","title":"US Research Roundup-Chevron, Exxon Mobil, GoDaddy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412443?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:58","pubTimestamp":1790319529,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddySept 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Chevron, Exxon Mobi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nL4N45H0CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["P","OILT","DRI","SO","STZ","INFQ","META","CMCSA","KMX","GPOR","CVX","XLP","CNK","ALM","AXGN","GDDY","CPT","FUL","CF","AEE","CGEM","UGE","CRK","NTRA","OKTA","CDNL","AKAM","RSPC","GRAL","LMRI","HELX","UPW","COST","XOM","KNF","FSTA","OBK","EMR","GEN","CRL","MMM","TRUC","BNY","ANDG","TRUN","FFBC","GXPE","DMRA","PYPL","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670492599","title":"Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2670492599","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670492599?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:22","pubTimestamp":1790266920,"startTime":"0","endTime":"0","summary":"Shares of Grail rose after the healthcare company said a U.S. regulatory committee voted to approve its Galleri multi-cancer early detection test.The stock was up 5.6% at $114.59 as of midday Thursday. Shares have risen 34% this year.The company on Wednesday said a panel on the Food and Drug Administration's Medical Devices Advisory Committee voted to approve its premarket approval application for Galleri.The panel voted seven to two with one abstention that the test's benefits outweigh its risks, six to four that the test was effective, and unanimously in support of its safety.\"Today's vote reinforces the strength of Galleri's clinical evidence. We believe the panel's recommendations reaffirm a high evidence bar that GRAIL has set for a multi-cancer early detection test,\" Grail Chief Executive Josh Ofman said. \"GRAIL is committed to working with the FDA as it completes its review of Galleri, the first PMA submission for a multi-cancer early detection test.\"Galleri received a breakthro","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4588","LABU","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499070","title":"FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499070","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499070?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"Mizuho's Bradley Bowers thinks the boost will be substantial. He wrote Tuesday that sales doubled in the launch years of other cancer-screening products-like colon cancer stool test Cologuard from the Exact Sciences unit of Abbott, or the colon cancer blood test Shield from Guardant Health.Galleri screens a person's blood sample for bits of DNA showing features typical of cancer cells. It tells you if it has found a general signal of cancer somewhere in your body-\"Cancer Signal Detected\"-and makes its best guess at the kind of tissue where the cancer is hiding.Clinical trials showed Galleri can detect cancers for which there is no standard screen, such as cancer of the ovary or pancreas. Grail's two big clinical trials showed that it rarely tells you that you have cancer when you don't. When you do have cancer, the test finds it on average about 50% of the 60% of the time.That is good performance, compared with other widely used screens, like the mammogram. Grail plans to tell customer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B4R5TH58.HKD","LABU","BK4568","LU0889565916.HKD","GNMX","SGXZ41872573.SGD","IE00B2B36J28.USD","LU2237957811.SGD","LU2468319806.SGD","LU2089984988.USD","BK4082","EKG","TMED","LU1989763690.USD","ABT","BK4139","BK4588","GH","IE0002141913.USD","IHI","LU0320765489.SGD","BK4535","SG9999002224.SGD","LU2112291526.USD","LFSC","BK4551","LU1670627923.USD","LU0211331839.USD","BK4196","BK4581","GNOM","LU0289739699.SGD","SG9999002232.USD","PJP","LU0882574055.USD","LU2324357040.USD","SGXZ23171101.USD","LU1691799644.USD","BK4585","GRAL","FFOX","PTH","LU0868494617.USD","LU1721429402.USD","LU1721429741.USD","SG9999004303.SGD","HELX","LU1061106388.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172071504","title":"Movement Alert｜GRAIL, Inc. Rises 5.97% in Regular Trading, FDA Advisory Committee Votes in Favor of Galleri Cancer Detection Test Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1172071504","media":"Market Focus","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172071504?lang=en_us&edition=fundamental","pubTime":"2026-09-24 21:58","pubTimestamp":1790258338,"startTime":"0","endTime":"0","summary":"On September 24, GRAIL, Inc. rose 5.97% in regular trading, trading at $114.925/share, with turnover of $67.12 million. The gain was driven by a landmark favorable vote from the FDA's Medical Devices...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GRAIL Soars as FDA Panel Backs Galleri Cancer Test Approval","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669349596","title":"TD ups Grail approval probability to 95% after panel vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2669349596","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669349596?lang=en_us&edition=fundamental","pubTime":"2026-09-24 21:20","pubTimestamp":1790256057,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Dan Brennan views the end result of the FDA panel meeting as solid for Grail (GRAL). The panel voted 7-2 with in favor of Galleri’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-ups-grail-approval-probability-to-95-after-panel-vote-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-ups-grail-approval-probability-to-95-after-panel-vote-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","BK4588","BK4585","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451354","title":"PRESS Digest -Wall Street Journal - September 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451354","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669451354?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:21","pubTimestamp":1790227304,"startTime":"0","endTime":"0","summary":"PRESS DIGEST -Wall Street Journal - September 24The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.- Barry Diller on Wednesday said he is withdrawing his bid for MGM ResortsMGM.Nafter months of discussions with the company.- An OpenAI agent infiltrated a government-services website in Australia this summer, Prime Minister Anthony Albanese said Wednesday at the United Nations meeting in New York.- Grail Inc.GRAL.Oreceived a favorable vote from a Food and Drug Administration panel regarding premarket approval for its Galleri multi-cancer early detection test.- Activist investor Starboard Value has taken a significant stake in construction company Knife RiverKNF.N, with plans to push the company to improve its margins or explore a sale.- Florida’s high-speed railroad Brightline is planning an imminent chapter 11 bankruptcy filing in New Jersey to restructure about $5.5 billion in debt.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4N45G07V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU1559883803.SGD","MGM","KNF","BK4150","BK4139","BK4561","LU1571399168.USD","LU0566484027.USD","ODDZ","BK4011","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669456881","title":"Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669456881","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669456881?lang=en_us&edition=fundamental","pubTime":"2026-09-24 11:35","pubTimestamp":1790220914,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Kyle Mikson CFA reiterated a Buy rating on GRAIL Inc today and set a price target of $80.00. Mikson CFA covers the Health...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-grail-inc-gral-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-grail-inc-gral-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","CFA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669289458","title":"RBC Capital Sticks to Their Hold Rating for GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669289458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669289458?lang=en_us&edition=fundamental","pubTime":"2026-09-24 09:45","pubTimestamp":1790214339,"startTime":"0","endTime":"0","summary":"In a report released on September 21, Dan Leonard from RBC Capital maintained a Hold rating on GRAIL Inc, with a price target of $84.00. The compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669431216","title":"Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2669431216","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669431216?lang=en_us&edition=fundamental","pubTime":"2026-09-24 06:35","pubTimestamp":1790202900,"startTime":"0","endTime":"0","summary":"Grail Inc. received a favorable vote from a Food and Drug Administration panel regarding premarket approval for its Galleri multi-cancer early detection test.The cancer-detection company said the FDA's medical devices advisory committee voted 7-2, with one abstention, to greenlight a premarket approval application for Galleri.The FDA isn't bound to the committee's recommendation, but it takes them into consideration when making the final regulatory decision. The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.In three separate votes, the 10 voting members of the committee considered Galleri's safety, effectiveness and overall benefit-risk profile for screening and early detection of multiple types of cancer in adults aged 50 and older.The Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer before symptoms appear, including cancers that don't have recommended screening today.When a cancer si","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABU","BK4588","BK4585","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669319284","title":"FDA panel votes in favor of Grail’s Galleri benefits outweighing risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669319284","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669319284?lang=en_us&edition=fundamental","pubTime":"2026-09-24 06:10","pubTimestamp":1790201424,"startTime":"0","endTime":"0","summary":"The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted to recommend approval for Grail’s (GRAL) Galleri, a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-panel-votes-in-favor-of-grails-galleri-benefits-outweighing-risks-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-panel-votes-in-favor-of-grails-galleri-benefits-outweighing-risks-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","BK4585","BK4139","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669397114","title":"US FDA Advisers Back Safety of Grail's Galleri Multi-Cancer Screening Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2669397114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669397114?lang=en_us&edition=fundamental","pubTime":"2026-09-24 05:31","pubTimestamp":1790199110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669431891","title":"FDA panel says Grail’s cancer detection blood test is safe, Bloomberg says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669431891","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669431891?lang=en_us&edition=fundamental","pubTime":"2026-09-24 05:30","pubTimestamp":1790199013,"startTime":"0","endTime":"0","summary":"17:26 EDT FDA panel says Grail’s (GRAL) cancer detection blood test is safe, Bloomberg says Published first on TheFly – the ultimate source for rea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-panel-says-grails-cancer-detection-blood-test-is-safe-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-panel-says-grails-cancer-detection-blood-test-is-safe-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","BK4139","BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669223436","title":"Grail CEO Joshua J. Ofman Disposes of Common Shares Worth $5.54 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669223436","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669223436?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:37","pubTimestamp":1790195863,"startTime":"0","endTime":"0","summary":"Grail CEO Joshua J. Ofman disposes of common shares worth $5.54 millionGrail CEO Joshua J. Ofman sold 61,452 common shares on Sep. 21, 2026, cutting his stake to 362,271 shares.Sales priced between US","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL4n4Sgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Grail CEO Joshua J. Ofman Disposes of Common Shares Worth $5.54 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485793","title":"FDA Advisers are Reviewing a Multicancer-Detection Test. Medicare Coverage Could Follow.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485793","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669485793?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:39","pubTimestamp":1790167140,"startTime":"0","endTime":"0","summary":"Grail's Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancersGrail sells the Galleri test, which screens for 50 types of cancer usi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669835544","title":"Grail Trading Halted Ahead of FDA AdCom Meeting on Galleri Blood Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2669835544","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669835544?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:52","pubTimestamp":1790164320,"startTime":"0","endTime":"0","summary":"Trading in shares of Grail is halted on Wednesday ahead of a Food and Drug Administration advisory committee meeting to discuss the diagnostic company's proposed multi-cancer blood test.Grail is seeking FDA approval of Galleri, a blood test that aims to catch cancers before symptoms appear.Shares of the Menlo Park, Calif., company were up 34% this week through Tuesday's close after FDA briefing documents for the meeting, released on Monday, were more favorable than investors had expected.RBC Capital Markets analyst Dan Leonard said the briefing documents suggest the FDA is less concerned with Galleri's safety and effectiveness and more focused on how to label the commercial product.The FDA often turns to advisory committees to obtain advice from experts who work outside of the government when a scientific, technical or policy question arises, such as whether an unapproved product is safe and effective. The agency usually follows the advice of its advisory committees but it isn't bound ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","BK4139","GRAL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669005631","title":"NASDAQ Trade Halt Halt News Pending at 06:55 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2669005631","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669005631?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:55","pubTimestamp":1790160900,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 06:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nAQN2MKEO5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669318122","title":"With Approval Looking Likely, How Fast Will Sales of Cancer-Screening Blood Tests Rise?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669318122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669318122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:10","pubTimestamp":1790107800,"startTime":"0","endTime":"0","summary":"This week's 35% jump in the stock of Grail pretty much prices in a positive vote Wednesday, when outside experts meet with the Food and Drug Administration to advise it on approving the first blood test for many kinds of cancer.With Grail now valued at $4.3 billion, or 19 times the consensus estimate for next year's sales, the stock already seems to be assuming the FDA will approve the test sometime early next year.Both those outcomes look likely. The advance questions posted Monday by the FDA for its advisors focus on the claims Grail should make in marketing its Galleri test to Americans over 50. The agency didn't question the test's safety and accuracy.Labs are permitted to sell tests they develop themselves. Grail is already selling Galleri, but the test is rarely covered by insurance. Last year, Grail had sales of about $150 million.Now the question for investors becomes what kind of sales boost will an approval deliver to Galleri?","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4568","LU2468319806.SGD","LU0211331839.USD","IE0009355771.USD","LU1721429402.USD","LU2211815571.USD","SG9999004303.SGD","LU1691799644.USD","LU0208291251.USD","LU1989763690.USD","ABT","LU1670627923.USD","SG9999002232.USD","SGXZ23171101.USD","IE00B4R5TH58.HKD","IHI","BK4585","BK4504","LU1023059063.AUD","LU2112291526.USD","LU1057294990.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU2237957811.SGD","LU0320765489.SGD","LU0266013472.USD","IE00BJT1NW94.SGD","SG9999002224.SGD","LU1061106388.HKD","LU1989763427.SGD","LU0882574055.USD","LU1914381329.SGD","PJP","TMED","BK4566","IE00BFTCPJ56.SGD","LU2237957902.USD","LU2133065610.SGD","SGXZ41872573.SGD","LU0432979614.USD","LU0122379950.USD","LU2324357040.USD","LU1983299246.USD","LU2089984988.USD","BK4139","GRAL","LU0114720955.EUR","LU1670628061.USD","BK4592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669512503","title":"Grail Gains From More Focused FDA Review Before Galleri Advisory Panel, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669512503","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669512503?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:26","pubTimestamp":1790094370,"startTime":"0","endTime":"0","summary":"Grail  faces an \"incrementally positive\" shift toward a narrower and more focused Food and Drug Administration debate ahead of Wednesday's advisory committee meeting on Galleri, its multicancer early detection test, UBS Securities said in a report.The FDA briefing documents show the agency has no major outstanding questions about Galleri's analytical performance, bridging analyses or primary safety results, UBS said Monday in the report. Instead, the panel discussion is expected to center on how the test should be positioned and labeled.A key issue is whether Galleri's stage-specific performance supports an \"early detection\" claim and how broadly any clinical benefit should be reflected in the final indication, the report said. UBS said it still expects FDA approval.UBS reiterated its buy rating on Grail stock with a $105 price target.Price: 108.40, Change: +0.43, Percent Change: +0.40","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","BK4588","LABU","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669397143","title":"Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669397143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669397143?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:55","pubTimestamp":1790070949,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Kyle Mikson CFA reiterated a Buy rating on GRAIL Inc yesterday and set a price target of $80.00. The company’s shares clo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CFA","GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669556196","title":"Under the Radar: Grail Shares Surge on FDA Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669556196","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669556196?lang=en_us&edition=fundamental","pubTime":"2026-09-22 06:57","pubTimestamp":1790031420,"startTime":"0","endTime":"0","summary":"Shares of Grail surged 34% Monday after the Food and Drug Administration released documents ahead of an advisory committee meeting Wednesday that will help determine whether the FDA approves the company's multi-cancer blood test.Galleri looks for chemical tags on DNA that tumors shed into the blood. The test flags a cancer signal and predicts the organ where the cancer is present. Grail has sold it by prescription since 2021, but the FDA has never approved a test that screens for multiple cancers.In a U.S. study of more than 25,000 adults, Galleri wrongly flagged cancer in 0.15% of healthy people. The test missed most cancers. It caught roughly one-third of those diagnosed within a year, in that study and in a U.K. trial of about 142,000 people. In the U.K. trial, it caught 14% of Stage 1 cancers, the earliest stage. The FDA has asked advisers whether those numbers justify calling Galleri an \"early detection\" test.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","GRAL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":128,"code":"91000000","status":"200"}]}}